Joo Hyun O MD, Abstract Co-Author: Nothing to Disclose

Edward A. Eikman MD, Abstract Co-Author: Nothing to Disclose

Jaime L Montilla-Soler,, Abstract Co-Author: Nothing to Disclose

Paul Eugene Kinahan PhD, Abstract Co-Author: Research Grant, General Electric Company Co-founder, PET/X LLC

James Michael Mountz MD, PhD, Abstract Co-Author: Nothing to Disclose

Eric Perlman, Abstract Co-Author: Nothing to Disclose

John Sunderland PhD, Abstract Co-Author: Nothing to Disclose

Heather Jacene MD, Abstract Co-Author: Nothing to Disclose

Nathan C. Hall MD, PhD, Abstract Co-Author: Consultant, Enlyton, Ltd

Michael Vinzenz Knopp MD, PhD, Abstract Co-Author: Nothing to Disclose

Abdel K. Tahari MD, PhD, Abstract Co-Author: Nothing to Disclose

Ronald Boellaard PhD, Abstract Co-Author: Nothing to Disclose

Otto S. Hoekstra MD, Abstract Co-Author: Nothing to Disclose

Li Huo, Abstract Co-Author: Nothing to Disclose

Hye Ok Kim, Abstract Co-Author: Nothing to Disclose

Sun Young Chae, Abstract Co-Author: Nothing to Disclose

Sae Jung Na, Abstract Co-Author: Nothing to Disclose

Sung Hoon Kim, Abstract Co-Author: Nothing to Disclose

Mike Sathekge, Abstract Co-Author: Nothing to Disclose

Moses Modiselle, Abstract Co-Author: Nothing to Disclose

Sally Barrington, Abstract Co-Author: Nothing to Disclose

Andrew Mark Scott, Abstract Co-Author: Nothing to Disclose

Sam Berlangieri, Abstract Co-Author: Nothing to Disclose

Andrew Quon MD, Abstract Co-Author: Speakers Bureau, Eli Lilly and Company Research Consultant, Koninklijke Philips Electronics NV

Jeffrey P. Leal BA, Abstract Co-Author: Nothing to Disclose

Muhammad Ali Chaudhry MD,MBBS, Abstract Co-Author: Nothing to Disclose

Richard L. Wahl MD, Presenter: Patents, Naviscan, Inc Patents, GlaxoSmithKline plc Patents, Spectrum Pharmaceuticals, Inc Research Consultant, GlaxoSmithKline plc Research Consultant, Nihon Medi-Physics Co, Ltd Research support, General Electric Company Research support, Molecular Insight Pharmaceuticals, Inc Research support, Cell Point LLC

To determine the variability in measurement of FDG uptake in normal liver background in identical human PET studies analyzed by differing readers, software and performance sites.

Baseline and post-therapy FDG PET/CT images of a single patient were distributed digitally to 15 sites in North America, Europe, Africa, Asia and Australia in an IRB approved study. Readers at each site measured the background activity by placing a 3 cm diameter spherical volume of interest (VOI) in right side of the liver. Workstation software from 8 different vendors were used for the quantification. The standard uptake value (SUV) and SUV corrected for lean body mass (SUL) were measured using local standard approaches.

The liver background SUV ranged from 1.47 to 2.19 at baseline with standard deviation (SD) of 0.16; and ranged from 1.80 to 2.96 (SD 0.26) at follow-up. The liver SUL measurements ranged from 0.91 to 1.56 (SD 0.12) at baseline; and from 1.20 to 2.02 (SD 0.17) at follow-up.

SUV and SUL measurements of the normal liver derived from the same set of FDG PET/CT images showed generally similar, but not consistently the same, values. The cause of the variance of liver measurements is likely due to both human VOI selection methods and software differences.

These results indicate that varying quantitative results can be extracted from identical PET/CT images and suggest the need to more fully standardize the PET analytic process.

O, J, Eikman, E, Montilla-Soler,, J, Kinahan, P, Mountz, J, Perlman, E, Sunderland, J, Jacene, H, Hall, N, Knopp, M, Tahari, A, Boellaard, R, Hoekstra, O, Huo, L, Kim, H, Chae, S, Na, S, Kim, S, Sathekge, M, Modiselle, M, Barrington, S, Scott, A, Berlangieri, S, Quon, A, Leal, J, Chaudhry, M, Wahl, R, QIBA2 FDG PET Reading Study: Variability of Liver FDG Uptake Measurements across Different Sites.  Radiological Society of North America 2013 Scientific Assembly and Annual Meeting, December 1 - December 6, 2013 ,Chicago IL. http://archive.rsna.org/2013/13024995.html